Introduction

52
For nearly a century, antibiotics have been a vital resource utilized by clinicians to 53 eliminate infection, with nearly 270 million prescriptions dispensed in 2015 alone. [1] Antibiotics 54 are utilized for a variety of infections, from common otitis externa ("swimmers ear") to severe 55 endocarditis, pneumonia, meningitis or osteomyelitis. Although antibiotics are typically able to 56 clear infection, antibiotic resistant strains of bacteria continue to emerge. It is not as lucrative, 57 nor as feasible, for pharmaceutical companies to develop novel antibiotics at the rates that these 58 multi-drug resistant (MDR) bacterial strains are isolated. Nationally, approximately $2.2 billion 59 is spent annually to treat MDR bacterial infections.
[2] By 2050, it is estimated that nearly 10 60 million people could die each year due to resistant strains of bacteria. [ 
3] 61
Staphylococcus aureus (S. aureus), a gram-positive bacterial strain, is one of the most 62 commonly isolated and arguably one of the most detrimental pathogens with antibiotic 63 resistance. One of the most common antibiotic resistant strains of S. aureus is methicillin-64 resistant S. aureus (MRSA). MRSA alone was responsible for over 80,000 reported infections in 65 2011 alone, of which 11,285 resulted in death.
[4] S. aureus is able to achieve antibiotic 66 resistance with genomic changes such as altered synthesis of peptidoglycan, a major component 67 of the bacterial cell wall. Additionally, some strains of S. aureus can produce biofilms, an 68 extracellular polymeric matrix including dead bacterial cells, which surrounds and protects the 69 living, underlying layer of S. aureus. [5] These biofilms can be difficult to penetrate, and 70 oftentimes require surgical intervention to remove. 71 4 Difficulties in treating osteomyelitis, or the infection of bone, have been exacerbated by 72 the rise of antibiotic resistant bacterial strains, particularly S. aureus strains, which are the most 73 common cause of bone infection. [6] Of diabetic foot ulcers, which occur in 25% of diabetic 74 patients, approximately 20% will spread to nearby bony hosts and result in osteomyelitis. [7] As 75 diabetic diagnoses continue to increase in the United States with an expected 55 million to be 76 afflicted by 2030, osteomyelitis infections will be an ongoing challenge for the healthcare 77 community. [8] It is essential that new therapeutics be engineered and tested, for rapid translation 78 into clinical use. 79
Bacteriophages (phages), or viruses that kill their bacterial hosts, are one class of 80 therapeutics that have gained attention in recent years due to their high specificity, non-toxicity, 81
and abundancy in nature.[9,10] Phages have been used for decades in Eastern Europe but have 82 not yet been adopted in the United States or other countries. This may be due to public concern 83 regarding elective viral use, issues concerning commercial phage production, and/or the ability to 84 fund and validate clinical trials.
[11] Nonetheless, the potential benefits of this treatment have 85 been indicated by results of clinical trials of phages for treating diabetic foot ulcers, chronic 86 otitis, and urinary tract infections [11] [12] [13] . In April 2019, data from clinical trials were published 87 from Sydney, Australia, where intravenous (IV) administration of phage was utilized for 88 Although the high specificity of phages can be beneficial for treating a known, single 99 species, specificity of these viruses can make polymicrobial infection mitigation challenging. In 100 the clinical scenario, it is ideal for health care providers to administer one broad-spectrum drug 101 immediately upon patient presentation, rather than spend time identifying the causative agents of 102 infection. Previously, we have utilized CRISPR-Cas9 to modify temperate bacteriophage, which 103 effectively removed major virulence genes and expanded host range via modifications to the tail 104 fiber protein (which codes host specificity). In vitro testing revealed the improvements of 105 bacteriophage bactericidal activity due to this CRISPR-Cas9 system.[21]Within 6h of treatment, 106 the CRISPR-Cas9 phage effectively killed 1x10 5 CFU S. aureus culture. With native, 107 unmodified phage treatment, the culture was found to increase to approximately 1x10 9 CFU. 108 Similar effects were noted in an in vivo dermal infection study, where CRISPR-Cas9 phage 109 treatment resulted in nearly complete mitigation of dermal infections (~1 log CFU/g tissue), 110 while treatment with unmodified phage resulted in a significantly higher bacterial load (~3.5 log 111
CFU/g tissue).[21] 112
The objectives of the present work were: (i) to develop a green fluorescent protein (GFP) 113 integrated S. aureus strain (ATCC 6538-GFP), modify bacteriophage using CRISPR-Cas9, and 114 evaluate the bactericidal efficacy of our CRISPR-Cas9 modified bacteriophage in vitro, 115 compared to conventional antibiotics, and (ii) to develop an in vivo model of osteomyelitis and 116 6 soft tissue infection using this biofilm forming S. aureus strain, and use it to assess the 117 antimicrobial effects of bacteriophage, antibiotic, and dual bacteriophage-antibiotic therapies via 118 histological, radiographic, and bacteriological analyses. Our hypothesis was that CRISPR-Cas9 119 modified bacteriophage would be effective against S. aureus infection in vitro and in the femur 120 and contiguous soft tissue in vivo. 121
122
Materials and Methods
123
Bacterial strains and culture 124 For a stable quantification of biofilm, S. aureus strain ATCC 6538 was genetically 125 modified to contain chromosomally integrated green fluorescent protein (GFP), as previously 126 described.
[22] Briefly, S. aureus strain ATCC 6538 was transduced with a temperature sensitive 127 plasmid pTH100 harboring the GFP gene by electroporation and cultured in a brain heart 128 infusion (BHI) agar plate supplemented with chloramphenicol (BHI-CM) at 30°C, a plasmid 129 replication permissive temperature. To promote the first homologous recombination and cure 130 pTH100, a single colony grown in a BHI-CM plate was transferred to a fresh BHI-CM plate and 131 cultured at 42°C, a plasmid replication non-permissive temperature. To promote the second 132 homologous recombination, which removed the plasmid and resulted in a loss of 133 chloramphenicol resistance but maintained the GFP phenotype, a single colony was inoculated 134 into BHI broth and cultured at 37°C overnight. A serial dilution of culture was inoculated onto a 135 BHI plate and incubated at 37°C overnight. A GFP positive single colony checked by ultraviolet 136 lamp was randomly selected and streaked onto BHI and BHI-CM. A colony that was both GFP 137 positive and sensitive to chloramphenicol, indicating the integration of the GFP gene into the 138 chromosome and removal of plasmid, was selected for experiments (ATCC 6538-GFP). 139 7 Preparation of alginate hydrogels 140 All alginate gels were initially prepared at a 3% (w/v) concentration, for ultimate dilution 141 to 2% after loading them with therapeutic. A 3% alginate mixture (w/v) was made with alginic 142 acid powder (Sigma-Aldrich) and alpha Minimum Essential Medium (αMEM, Gibco) then left 143 overnight at room temperature. This solution was sterile filtered (0.2 μm, Pall) and transferred 144 into 1mL syringes. Therapeutics were then added directly to the alginate. The crosslinker, 145 calcium sulfate (0.21g CaSO4 / mL distilled H2O) was loaded into a separate 1mL syringe and 146 was mixed vigorously with the alginate solution for approximately one minute. Hydrogels were 147 kept at 4°C or on ice until use. 148 
Synthesis of CRISPR-Cas9 modified bacteriophages
Kirby-Bauer analyses 157
To analyze the bactericidal activity of therapeutics, a Kirby-Bauer assay was performed 158 as previously described, with slight modifications.
[23] Stock solutions of fosfomycin (50 159 mg/mL) and phage (~10MOI/mL) were prepared in phosphate buffered saline (PBS). Using 160 these stock solutions, a total of 10μL of: (i) fosfomycin, (ii) phage, (iii) dual: fosfomycin (5μL) 161 and phage (5 μL), or (iv) PBS alone were directly applied to bacterial lawns, without the use of 162 8 disks as traditionally described. The applied solutions were allowed to set undisturbed for 163 approximately 5-10 minutes at room temperature, and were then incubated at 37°C for 24h. The 164 zones of inhibition were then measured and recorded. 165
Qualitative and quantitative bactericidal activity on biofilms 166 For qualitative in vitro evaluation of antibiofilm efficacy, a 6-well tissue culture plate was 167 pre-coated with 2% human serum for 24 hours, after which Staphylococcus aureus ATCC 6538-168 GFP was cultured in tryptic soy broth (TSB) supplemented with 2% glucose for 72 hours. After 169 gentle washing with PBS, TSB supplemented with vancomycin (256, 512, or 1024 μg/mL), 170 fosfomycin (16, 64, 128 μg/mL) or bacteriophage (5, 10, or 25 multiplicity of infection (MOI)) 171 was added to the biofilm and incubated for 24 hours. After gentle washing with PBS three times, 172 remaining biofilm indicated by GFP signal was measured using Cytation 5 plate reader (BioTek). 173
To quantify the antibiofilm activity of selected therapeutics delivered by alginate 174 hydrogels, fosfomycin, phage, or dual therapeutic was loaded in 2% alginate hydrogel and 175 overlaid on top of the biofilms. As a control, empty 2% alginate hydrogel was used. BHI broth 176 was added and cultures were incubated at 37°C for 24 h. After removing BHI broth, the entire 177 2% alginate hydrogel and biofilm were harvested and vigorously washed with PBS by 178 centrifugation to remove residual therapeutic. A serial dilution in PBS was plated onto BHI 179 plates to determine viable bacterial counts. 180 infected screw was removed and placed into 1mL PBS or fixative for bacterial counting or SEM, 208 10 respectively. Then, 100 µL of fosfomycin (3 mg), phage (MOI 3), dual (3 mg fosfomycin and 209 MOI 3 phage), or PBS loaded into 2% alginate hydrogel was injected into the lateral end of the 210 bicortical defect, with excess hydrogel pooling in the medial, underlying soft tissue. 211
Rat osteomyelitis model
On day 8, approximately 24 hours post-treatment, animals were sacrificed via CO2 212 inhalation. The hindlimb was initially cleaned with chlorhexidine, and sterile instruments were 213 used to disarticulate the femur and adjacent soft tissues for further evaluation. For bacterial 214 counting, bone samples were initially minced using sterile bone rongeurs and further processed 215 using a homogenizer (Cole-Parmer, LabGEN7, 30s at setting 2-3, 30s at setting 9-10). Soft tissue 216 samples were minced using sterile surgical scissors, then homogenized (30s at setting 2-3, 30s at 217 setting 7-8). Following initial processing, homogenates were vortexed (2000 RPM, 1 minute), 218 diluted as necessary, spread onto BHI agar plates, and incubated for 24 hours at 37°C for 219 enumeration, with a detection limit set at 25-250 colonies. 220 have been most commonly used; however, it is necessary to constantly provide antibiotic 260 selective pressure to prevent a loss of plasmid, which is not achievable with in vivo models. In 261 this study, we integrated the GFP reporter gene into the genome of S. aureus ATCC 6538 strain 262 for the stable and accurate assessment of bacterial growth. All S. aureus ATCC 6538-GFP 263 colonies grown in BHI plates without antibiotic selective pressure were highly fluorogenic over a 264 span of 7 days ( Fig. 2A ). Furthermore, ATCC 6538-GFP recovered from an ex vivo orthopedic 265 screw at day 7 post-infection was still highly fluorogenic (Fig. 2B) . These results demonstrated 266 that S. aureus ATCC 6538 chromosomally integrated with GFP can be used for real-time 267 monitoring of bacterial proliferation in vitro and in vivo. 
Kirby-Bauer analyses 273
For initial investigation of selected therapeutics, a Kirby-Bauer assay was performed 274 (Fig. 3A) . All therapeutics-fosfomycin, phage, and dual-had a larger zone of inhibition than 275 13 the PBS control ("a", p<0.0001), which generated no zone of inhibition ("N.D.") Dual and 276 fosfomycin also resulted in a zone of inhibition greater than phage treatment ("b," p<0.0001). 277 difficult osteomyelitis cases, appeared to have little or no effect on biofilms, as indicated by the 306 presence of green fluorescing S. aureus (Fig. 3B ). Fosfomycin is a small molecular weight (138 307 g/mol) broad-spectrum antibiotic and promising therapeutic option against biofilm.
[26] Here, 308 fosfomycin appeared to remove biofilm at 64 and 128 µg/mL, doses much lower than 309 vancomycin. The CRISPR-Cas9 modified bacteriophage has dual killing mechanisms: (i) a direct 310 lysis of target bacteria by holin or murein hydrolase, and (ii) CRISPR-Cas9 nuclease activity. 311
From qualitative fluorescent analyses, it was determined than a phage MOI of ~10 was effective 312 in clearing biofilm infection (Fig. 3B) . 313
Alginate is a versatile biopolymer used for prolonged, localized availability of 314 therapeutic.
[27] Antibiofilm assays with bacterial counts were utilized to qualitatively assess the 315 effects over time of selected therapeutics delivered via alginate (Fig. 3C ). Compared to the 316 empty alginate group, fosfomycin, phage, and dual therapeutic-treated biofilms had significantly 317 lower bacterial loads at 6, 12, and 24 hours, except the fosfomycin group at 6 hours ("c," 318 p<0.05). Interestingly, all groups (fosfomycin, phage, dual, and empty alginate gel) were 319 significantly lower at all time points compared to the PBS treatment, i.e. the empty alginate gel 320 exerted a killing effect ("s", p<0.05). In all treatment groups where alginate was loaded with 321 therapeutic(s), antibiofilm effects increased over time. The fosfomycin treated biofilms were 322 different at 6 and 12 hours, and at 12 and 24 hours (**p<0.0001). Phage treated groups were 323 different at 6 and 12 hours, and at 6 and 24 hours (*p<0.05). Dual treated biofilms were different 324 at 6 and 12 hours, at 6 and 24 hours, and at 12 and 24h (**p<0.0001). As expected, the empty 325 alginate and PBS controls did not change over time. 326
Bacterial load on orthopedic screws 327
To generate consistent infection in the osteomyelitis model, contaminated orthopedic 328 screw preparation had to first be characterized. Two parameters of screw preparation were 329 evaluated: soak time and dry time. Soak time (5-20 min) of screws appeared to increase 330 somewhat proportionally with respect to bacterial load (Fig. 4A ). Dry times from 0-10 min 331 appeared to have little effect on bacterial load; at 20 min, decreased viability of S. aureus was 332 observed (Fig. 4B) . 333
In the in vivo model, orthopedic screws removed at day 7 to allow injection of therapeutic 334 into the infected defect space were analyzed for bacterial load to confirm all treatment groups 335 began with a similar extent of infection. Bacterial counts from ex vivo screws indicated similarly 336 severe infection among all samples (treated immediately following), with an average 8.19x10 4 337 CFU/mL bacterial load (Fig. 4C ). Per what would become individual treatment groups, 338 calculated averages were: 1.05x10 5 , 7.50x10 4 , 8.20x10 4 , and 6.57x10 4 for fosfomycin, phage, 339 dual, and control groups, respectively. No significant differences between any groups were 340 observed. 341 and within the ridges of the screw throughout its length ( Fig. 5A-B ). In bone fragments collected 353 along the screw line (defect site) of an untreated (empty alginate) control sample at day 8 (24h 354 post-treatment), gram positive cocci, presumably S. aureus, were visible. (Fig. 5C-D) . 355 the proliferation of woven bone, as a reactive process on the cortical surface, is visible (Fig. 7B) . 387
Within the phage-treated bone sample, a linear track of gram-positive bacteria in the bone at the 388 original site of the screw line was visible (Fig. 7C ). In the dual-treated sample, neutrophilic 389 inflammation surrounded by reactive bone and fibrosis was observed ( Fig.7D left, *) . biofilm may be explained by poor penetration of vancomycin due to its bulky size, which could 428 have led to entrapment at the peptidoglycan layer of biofilm. In contrast, fosfomycin showed 429 better efficacy against biofilm at much lower (64 and 128 µg/mL) doses. Fosfomycin is a small 430 bactericidal antibiotic with a molecular weight of 138 g/mol. It interferes with the first step of 431 peptidoglycan synthesis by inhibiting the phosphoenolpyruvate synthetase [30] . Thus, the 432 enhanced fosfomycin efficacy could be explained by better penetration of fosfomycin due to its 433 small size and its inhibition of the first step of peptidoglycan synthesis. From qualitative 434 fluorescent analyses, it was determined than a phage MOI of ~10 was effective in clearing 435 biofilm infection. This is similar and in some cases an improvement upon in vitro evaluation of 436 20 phage treatments discussed in literature, with biofilm eradication reported with MOI 10-437 100.[21,31,32] Alginate hydrogel served as an effective delivery vehicle, enabling increasing 438 effects against biofilm over a 24h period, for fosfomycin, phage, and dual treatments in vitro. 439 Previously, we have observed similar sustained effects of bone morphogenetic protein-2 released 440 from and retained within alginate hydrogels in vitro and in vivo. [18, 27] correlation between radiance output and bacterial load were observed (data not shown). This 450 could be attributed at least in part to a residual GFP signal that likely exists after bacterial cell 451 death, due to the persistence of the GFP. Clinically, debridement accompanied by long-term 452 antibiotic administration is the gold standard for osteomyelitis treatment. [33] In this study, we 453 have avoided debridement altogether so as to limit potential clearing of infection from any 454 source other than the therapeutics delivered. For future studies, debridement may be included to 455 more readily mimic the clinical scenario and enable evaluation of larger antibacterial materials 456 such as scaffolds or putties. 457
From bacterial counts performed on excised soft tissues, it was determined that severe 458 soft tissue infection accompanied the expected high bacterial load in the bone samples. In 459 21 clinical cases of osteomyelitis, soft tissue infection is a common pathological finding of 460 osteomyelitis infection progression [34] [35] [36] hour time frame of this study, no differences among treatment groups were apparent. If later time 470 points were evaluated, the differences noted in bacterial counting would likely be more readily 471 reflected histologically. 472
Although only the fosfomycin group resulted in reduced bacterial load in the femur, in 473 soft tissue, all three treatments, including phage alone and phage with fosfomycin (dual) led to 474 lower bacterial counts compared to empty alginate. It should be noted than an extremely high 475 dose of fosfomycin (3g) was administered to the rat femur in this study. In humans, a 3g oral 476 dose is recommended for treatment of urinary tract infections.
[26] Conversely for bacteriophage 477 dose, although a minimum effective MOI of ~10 was observed in vitro, in vivo only MOI of ~3 478 was able to be delivered due to: (i) the volume of alginate hydrogel delivered to the small defect 479 site (100 µL total, but only ~10 µL fit into the defect itself), and (ii) the thicker consistency of 480 phage solution, limiting the concentration that could be prepared in alginate hydrogel. 481
Collectively, these discrepancies in dosing likely limited the efficacy of phage treatment alone in 482 
